10-40mg nocte. Adjusted at an interval of not less than 4 weeks.
Mode of action
Brands containing this Ingredient
Drug Index 2.0 is hereOur new update features a more powerful search feature and easier login.
issues? Contact us
today. Contact Us
Mode of Action
Competitively inhibits 3- hydroxy-3 methylglutaryl co-enzyme A [HMG- COA] reductase - the enzyme which catalyses the early rate limiting step in cholesterol biosynthesis-conversion of HMG-Co A to mevalonate.
Monitor liver functions; heavy alcoholics; rhabdomyolysis.
Pregnancy and lactation; hypersensitivity; active liver disease or unex- plained persistent defects in liver function tests; children under 18 years; impaired renal functions.
GI disturbances; myopathy; insom-
nia; UTI; tooth disorders; sinusitis.